Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.66 +0.6%	$1.96	$1.56 ▼ $6.31	$441.72M	2.07	1.40 million shs	697,449 shs
ELUT Elutia	$2.64 -0.8%	$2.97	$2.28 ▼ $5.24	$107.55M	0.86	46,840 shs	16,857 shs
STOK Stoke Therapeutics	$7.21 -3.2%	$9.32	$6.82 ▼ $17.58	$389.90M	0.99	721,207 shs	572,399 shs
TRML Tourmaline Bio	$16.65 -0.5%	$15.26	$11.87 ▼ $29.79	$427.66M	2.35	273,823 shs	184,681 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	0.00%	-2.35%	-4.05%	-24.89%	-73.98%
ELUT Elutia	0.00%	-9.59%	-19.51%	-32.13%	-16.19%
STOK Stoke Therapeutics	0.00%	-11.53%	-8.15%	-33.24%	-46.59%
TRML Tourmaline Bio	0.00%	-2.92%	+27.20%	-17.08%	-27.29%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	3.0027 of 5 stars	3.5	2.0	0.0	3.4	3.3	0.6
ELUT Elutia	4.0551 of 5 stars	3.5	5.0	0.0	3.3	5.0	0.6
STOK Stoke Therapeutics	3.552 of 5 stars	3.6	0.0	4.8	2.8	1.7	0.0
TRML Tourmaline Bio	1.9475 of 5 stars	3.5	1.0	0.0	2.7	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.52	473.49% Upside
ELUT Elutia	3.00	Buy	$9.00	240.91% Upside
STOK Stoke Therapeutics	3.13	Buy	$24.67	242.12% Upside
TRML Tourmaline Bio	3.00	Buy	$45.20	171.47% Upside

Current Analyst Ratings Breakdown

Latest ELUT, AUTL, TRML, and STOK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/21/2025	AUTL Autolus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$8.00 ➝ $6.00
3/19/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$47.00 ➝ $47.00
3/19/2025	STOK Stoke Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
3/18/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
3/14/2025	TRML Tourmaline Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$42.00 ➝ $43.00
3/14/2025	TRML Tourmaline Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$49.00 ➝ $50.00
3/7/2025	ELUT Elutia	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00 ➝ $8.00
3/6/2025	TRML Tourmaline Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$42.00
2/24/2025	TRML Tourmaline Bio	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$58.00
2/19/2025	STOK Stoke Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
2/18/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $47.00

(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$10.12M	43.65	N/A	N/A	$0.64 per share	2.59
ELUT Elutia	$24.38M	4.41	N/A	N/A	($1.66) per share	-1.59
STOK Stoke Therapeutics	$36.56M	10.67	N/A	N/A	$3.57 per share	2.02
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$10.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$208.38M	-$0.86	N/A	N/A	N/A	N/A	-63.65%	-36.54%	5/16/2025 (Estimated)
ELUT Elutia	-$37.66M	-$2.47	N/A	N/A	N/A	-218.72%	N/A	-142.61%	5/8/2025 (Estimated)
STOK Stoke Therapeutics	-$104.70M	-$1.68	N/A	N/A	N/A	-629.90%	-54.45%	-40.77%	5/5/2025 (Estimated)
TRML Tourmaline Bio	-$42.12M	-$2.87	N/A	N/A	N/A	N/A	-20.97%	-20.56%	5/12/2025 (Estimated)

Latest ELUT, AUTL, TRML, and STOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/24/2025	Q4 2024	STOK Stoke Therapeutics	-$0.56	-$0.18	+$0.38	-$0.18	$4.20 million	$22.61 million
3/20/2025	Q4 2024	AUTL Autolus Therapeutics	-$0.21	-$0.09	+$0.12	-$0.09	$2.98 million	$0.03 million
3/13/2025	Q4 2024	TRML Tourmaline Bio	-$0.91	-$0.86	+$0.05	-$0.86	N/A	$0.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
ELUT Elutia	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	13.69	13.69
ELUT Elutia	N/A	0.94	0.85
STOK Stoke Therapeutics	N/A	5.09	5.09
TRML Tourmaline Bio	N/A	40.33	40.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
ELUT Elutia	74.03%
STOK Stoke Therapeutics	N/A
TRML Tourmaline Bio	91.89%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
ELUT Elutia	40.80%
STOK Stoke Therapeutics	11.30%
TRML Tourmaline Bio	11.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.09 million	197.71 million	Optionable
ELUT Elutia	180	40.74 million	20.46 million	Not Optionable
STOK Stoke Therapeutics	100	54.08 million	46.98 million	Optionable
TRML Tourmaline Bio	44	25.69 million	22.82 million	Optionable

ELUT, AUTL, TRML, and STOK Headlines

Recent News About These Companies

Swiss National Bank Takes Position in Tourmaline Bio, Inc. (NASDAQ:TRML)

March 31 at 3:11 AM | marketbeat.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of "Buy" by Analysts

March 16, 2025 | marketbeat.com

Tourmaline Bio (NASDAQ:TRML) Given New $43.00 Price Target at Wedbush

March 15, 2025 | marketbeat.com

TOURMALINE BIO Earnings Results: $TRML Reports Quarterly Earnings

March 15, 2025 | nasdaq.com

Tourmaline Bio (TRML) Gets a Buy from Wedbush

March 15, 2025 | markets.businessinsider.com

Tourmaline Bio (NASDAQ:TRML) Stock Price Expected to Rise, HC Wainwright Analyst Says

March 15, 2025 | marketbeat.com

Tourmaline Bio price target raised to $43 from $42 at Wedbush

March 14, 2025 | markets.businessinsider.com

Tourmaline Bio (NASDAQ:TRML) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS

March 14, 2025 | marketbeat.com

Tourmaline Bio, Inc.: Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

March 14, 2025 | finanznachrichten.de

Tourmaline Bio reports Q4 EPS (86c), consensus (87c)

March 14, 2025 | markets.businessinsider.com

Tourmaline Bio shares fall as Q4 loss widens

March 14, 2025 | investing.com

Tourmaline Bio sees cash runway into 2H27

March 14, 2025 | markets.businessinsider.com

Tourmaline Bio’s 2024 Financial Results and Strategic Advances

March 14, 2025 | tipranks.com

Tourmaline Bio, Inc. Announces Over-Enrolled Phase 2 TRANQUILITY Trial and Strengthens Cardiovascular Scientific Advisory Board Amid Positive Financial Outlook

March 13, 2025 | quiverquant.com

Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

March 13, 2025 | globenewswire.com

Tourmaline Bio (TRML) Projected to Post Earnings on Tuesday

March 11, 2025 | marketbeat.com

Piper Sandler Sticks to Their Buy Rating for Tourmaline Bio (TRML)

March 10, 2025 | markets.businessinsider.com

Wedbush Forecasts Tourmaline Bio FY2024 Earnings

March 10, 2025 | marketbeat.com

Wedbush bullish on Tourmaline Bio, initiates with an Outperform

March 7, 2025 | markets.businessinsider.com

Wedbush Initiates Coverage of Tourmaline Bio (TRML) with Outperform Recommendation

March 7, 2025 | msn.com

Tourmaline Bio (NASDAQ:TRML) Earns Outperform Rating from Analysts at Wedbush

March 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELUT, AUTL, TRML, and STOK Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$1.66 +0.01 (+0.61%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$1.75 +0.09 (+5.66%)

As of 03/28/2025 05:39 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Elutia NASDAQ:ELUT

$2.66 +0.00 (+0.15%)

As of 03/28/2025 04:00 PM Eastern

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Stoke Therapeutics NASDAQ:STOK

$7.21 -0.24 (-3.22%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$7.21 0.00 (0.00%)

As of 03/28/2025 04:05 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Tourmaline Bio NASDAQ:TRML

$16.65 -0.08 (-0.48%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$16.18 -0.47 (-2.83%)

As of 03/28/2025 07:58 PM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time